OGN

Organon & Co. is a leading global pharmaceutical company based in Jersey City, specializing in women's health and dedicated to advancing the health and well-being of women worldwide. The company's diverse portfolio encompasses critical areas such as reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia, allowing it to comprehensively address unmet health needs. With an emphasis on innovation and leveraging deep industry expertise, Organon is well-positioned to capitalize on the growing demand for specialized women's health interventions, making it an attractive investment opportunity for institutional investors seeking to enhance their footprint in the healthcare sector.